2 results
Approved WMOCompleted
To evaluate the relationship of developmental stage (defined by both gestational and postnatal age) to UGT2B7 activity (as determined by CLf,M3G and CLf,M6G).To evaluate the relationship of UGT2B7 genetic variability to UGT2B7 activity (as…
Approved WMOCompleted
Run-in phase I: To confirm the safety and tolerability of BIBF 1120 up to a dose level of 200 mg b.i.d added to a standard dose of cisplatin/gemcitabine in first line NSCLC patients with squamous cell histology. Pharmacokinetics of BIBF 1120 and…